The Relation Between the Prognosis of Subthalamic Nucleus Deep Brain Stimulation Surgery by Microlesion Effect and Electrode Position

Summary

BACKGROUND: Parkinson's disease (PD) is a common movement disorder whose main symptoms include resting tremor, rigidity and bradykinesia. Deep Brain Stimulation (DBS) has become one of the most effective treatments for PD by implanting electrodes in specific deep brain nuclei to alleviate motor symptoms in PD patients. During the implantation of electrodes in the DBS procedure, small lesions produced are known as the Microlesion Effect, which disappears within a short period. The MLE efficacy is positively correlated with the overall efficacy of DBS, but whether the MLE efficacy is affected by the symptoms has not yet been investigated, and a large-sample study is needed to further validate this. This study aims to examine the relationship between electrode implantation location and the prediction of MLE efficacy produced by STN-DBS surgery in PD patients, assess the correlation between electrode implantation location and DBS efficacy in PD patients, and analyze the role of brain networks in the process. The study will also analyze the relationship between micro-destructive effects and long-term DBS efficacy, providing more effective efficacy prediction and a more accurate selection of electrode implantation locations for DBS treatment in PD patients. This study will guide the clinical practice of DBS treatment in PD patients and provide an important reference for future research in related fields.

Object: Primary Parkinson's Disease patients between the ages of 18 and 75 years who meet STN-DBS surgery criteria Aim: To observe the relationship between predicted efficacy and implantation location of STN-DBS for MLE in PD surgery

Conditions

• Parkinson's Disease (PD)
• Deep Brain Stimulation

Interventions

OTHER

the score of UPDRS item

The score of MDS-UPDRS item 3.1 greater or equal to 2 during the drug-off period at baseline

OTHER

the score of UPDRS item

The score of MDS-UPDRS item 3.3 greater or equal to 2 during the drug-off period at baseline

OTHER

the score of UPDRS item

The score of MDS-UPDRS item 3.10 greater or equal to 2 during the drug-off period at baseline

OTHER

the score of UPDRS item

Any one of the MDS UPDRS 3.15-3.17 scores greater or equal to 2 during the drug-off period at baseline

OTHER

the score of UPDRS item

Sum of MDS UPDRS 4.1-4.2 scores greater than or equal to 3

Sponsors & Collaborators

• Beijing Pins Medical Co., Ltd

  collaborator INDUSTRY

• Second Affiliated Hospital of Nanchang University

  lead OTHER

Eligibility

Min Age

18 Years

Max Age

75 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2023-11-06

Primary Completion

2026-07-01

Completion

2026-07-01

Countries

• China

Study Locations